First National Trust Co Sells 428 Shares of Edwards Lifesciences Co. (NYSE:EW)

First National Trust Co cut its holdings in Edwards Lifesciences Co. (NYSE:EW) by 10.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,750 shares of the medical research company’s stock after selling 428 shares during the quarter. First National Trust Co’s holdings in Edwards Lifesciences were worth $247,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in EW. GSA Capital Partners LLP purchased a new stake in shares of Edwards Lifesciences during the third quarter valued at $481,000. Entropy Technologies LP bought a new position in Edwards Lifesciences during the 3rd quarter valued at about $2,069,000. Versor Investments LP boosted its holdings in shares of Edwards Lifesciences by 102.5% during the 3rd quarter. Versor Investments LP now owns 4,455 shares of the medical research company’s stock valued at $294,000 after acquiring an additional 2,255 shares during the last quarter. Addison Advisors LLC grew its stake in shares of Edwards Lifesciences by 915.1% in the third quarter. Addison Advisors LLC now owns 18,038 shares of the medical research company’s stock worth $1,190,000 after acquiring an additional 16,261 shares during the period. Finally, Patten & Patten Inc. TN raised its holdings in shares of Edwards Lifesciences by 7.5% during the third quarter. Patten & Patten Inc. TN now owns 164,904 shares of the medical research company’s stock valued at $10,882,000 after purchasing an additional 11,512 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $66.52 on Thursday. The stock has a 50-day moving average price of $67.47 and a 200 day moving average price of $76.51. The stock has a market capitalization of $39.23 billion, a P/E ratio of 9.60, a P/E/G ratio of 3.70 and a beta of 1.12. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period in the prior year, the company posted $0.59 EPS. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 41,250 shares of company stock worth $2,744,438. Insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Bank of America downgraded shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and cut their target price for the stock from $105.00 to $75.00 in a research report on Thursday, July 25th. Barclays reduced their price objective on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Robert W. Baird dropped their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Wells Fargo & Company reduced their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Finally, Baird R W downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 25th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $75.67.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.